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Abstract 
Objective: To examine the pre-clinical and clinical evidence for the use of oxaliplatin 
or paclitaxel salvage chemotherapy in patients with cisplatin-resistant cancer.  
Methods: Medline was searched for 1) Cell models of acquired resistance reporting 
cisplatin, oxaliplatin and paclitaxel sensitivities and 2) Clinical trials of single agent 
oxaliplatin or paclitaxel salvage therapy for cisplatin/carboplatin-resistant ovarian 
cancer. Results: Oxaliplatin - Oxaliplatin is widely regarded as being active in 
cisplatin-resistant cancer. In contrast, data in cell models suggests that there is cross-
resistance between cisplatin and oxaliplatin in cellular models with resistance levels 
which reflect clinical resistance (<10 fold). Oxaliplatin as a single agent had a poor 
response rate in patients with cisplatin-resistant ovarian cancer (8%, n=91). 
Oxaliplatin performed better in combination with other agents for the treatment of 
platinum-resistant cancer suggesting that the benefit of oxaliplatin may lie in its more 
favourable toxicity and ability to be combined with other drugs rather than an 
underlying activity in cisplatin resistance. Oxaliplatin therefore should not be 
considered broadly active in cisplatin-resistant cancer. Paclitaxel – Cellular data 
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suggests that paclitaxel is active in cisplatin-resistant cancer. 68.1% of cisplatin-
resistant cells were sensitive to paclitaxel. Paclitaxel as a single agent had a response 
rate of 22% in patients with platinum-resistant ovarian cancer (n = 1918), a significant 
increase from the response of oxaliplatin (p<0.01). Paclitaxel-resistant cells were also 
sensitive to cisplatin, suggesting that alternating between agents may be beneficial. 
Studies of single agent paclitaxel in platinum-resistant ovarian cancer where patients 
had previously received paclitaxel had an improved response rate of 35.3% n=232 
(p<0.01), suggesting that pre-treatment with paclitaxel improves the response of 
salvage paclitaxel therapy.  
Conclusions: Cellular models reflect the resistance observed in the clinic as the cross 
resistant agent oxaliplatin has a lower response rate compared to the non-cross 
resistant agent paclitaxel in cisplatin-resistant ovarian cancer. Alternating therapy 
with cisplatin and paclitaxel may therefore lead to an improved response rate in 
ovarian cancer. 
 
Keywords:  Cisplatin, Oxaliplatin, Paclitaxel, Resistance, Ovarian Cancer, 
Salvage Chemotherapy 
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Chapter  
Oxaliplatin has been widely regarded as potentially useful for the treatment of 
cisplatin-resistant cancer. The evidence cited for oxaliplatin’s activity in cisplatin-
resistant cancer comes in general from studies of highly cisplatin-resistant cell lines 
with low-level oxaliplatin resistance or review articles summarising these findings 
and oxaliplatin in general. While highly resistant models are useful to understand the 
possible mechanisms of resistance, drug resistance in the clinical setting typically 
occurs at lower levels of resistance (1;2) and may therefore involve different 
mechanisms of resistance. 
 
Cisplatin and oxaliplatin target the DNA whereas paclitaxel, a taxane, causes toxicity 
by stabilising polymerised microtubules. Due to their differing mechanisms of action 
platinums and taxanes are often combined in cancer therapy. Our laboratory has found 
that when cells become resistant to platinum they often become sensitive to taxanes 
(3;4). Preliminary reading of the literature also suggested that the reverse is also true 
i.e. that taxane-resistant cell lines can be sensitive to platinum. We undertook this 
systematic review to identify, describe and critique the clinical and cellular evidence 
for the use of oxaliplatin or paclitaxel in patients with cisplatin-resistant cancer. 
 
Resistant cell models are developed in the laboratory by repeatedly exposing cancer 
cells in culture to chemotherapy. The surviving resistant cells are then compared to 
the parental sensitive cells using a cell viability assay such as the MTT or clonogenic 
assay. The IC50 (drug concentration causing 50% growth inhibition) for these paired 
cell lines can be used to determine the increase in resistance known as fold resistance 
by the following equation:-  
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Fold Resistance = IC50 of Platinum Resistant Cell Line / IC50 of Parental Cell Line 
 
The literature search for models of acquired platinum resistance which report cross 
resistance data for both cisplatin and oxaliplatin identified 27 cell lines (5). For each 
cell line the fold oxaliplatin resistance was plotted against the fold cisplatin resistance, 
allowing an analysis of the pattern of cross resistance (Figure 1A). The definition of 
cross resistance is a matter of debate in the literature. Some studies consider two drugs 
cross-resistant only if a similar level of resistance is observed. For the purposes of this 
review we have defined cross resistance between cisplatin and oxaliplatin as greater 
than or equal to 2-fold resistance to both drugs. This definition is therefore based on 
what would be clinically observed as cross resistance. 
 
Figure 1A shows that the majority of models of acquired platinum resistance are 
cross-resistant to both cisplatin and oxaliplatin having at least 2-fold resistance to both 
drugs. The lower level resistant models, below 10-fold, tend to be cross-resistant to a 
similar level to both drugs. However, the higher level resistant models, above 10-fold, 
are highly resistant to their selecting drug and then exhibit a lower level of resistance 
to the other drug. This suggests that a common mechanism of low-level resistance to 
both cisplatin and oxaliplatin develops at clinical levels of drug treatment. Whereas 
the resistance mechanisms that develop at higher drug concentrations are likely to be 
more specific for the selecting drug. This is in contrast with the cross resistance 
relationship between cisplatin and carboplatin which shows cross resistance at low 
and high level resistance, indicated by grey shading (6) (Figure 1B). 
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The literature search for models of acquired resistance which report cross resistance 
data for both cisplatin and paclitaxel identified 137 cell lines (6). For each cell line the 
fold paclitaxel resistance was plotted against the fold cisplatin resistance, allowing an 
analysis of the pattern of cross resistance between the two compounds (Figure 2A). 
13.9% of cell lines found in the literature review were below 2-fold resistance to both 
compounds and therefore classed as non-resistant indicated with black stars in Figure 
2A. It is the minority of cell models of acquired resistance which are cross-resistant 
(open circles) to both cisplatin and paclitaxel (16.8%). The majority of cells are either 
non-cross resistant (grey circles 40.9%), with no gain of resistance to the other 
compound, or hypersensitive (black circles 28.5%) becoming more sensitive than the 
parental cancer cell line they were derived from. 71 cell lines were resistant to 
cisplatin, 48 of these were non-cross resistant or hypersensitive to paclitaxel (67.6%). 
69 cell lines were resistant to paclitaxel, 46 of these were non-cross resistant or 
hypersensitive to cisplatin (66.6%). This suggests an inverse relationship between 
cisplatin and paclitaxel resistance in resistant cell models where resistance to one 
leads to sensitivity to the other. A similar inverse relationship was observed between 
cisplatin and docetaxel, carboplatin and paclitaxel and carboplatin and docetaxel, 
suggesting that an inverse resistance relationship exists between platinum and taxane 
chemotherapy (6). 
 
The resistant cell lines found in the cisplatin/paclitaxel systematic review were diverse 
in type of carcinoma (Figure 2B). Ovarian (45.3%) and SCLC (21.2%) were the most 
common carcinomas used to develop cell lines, however, the other 16 types of 
carcinoma suggest that the inverse relationship between cisplatin and paclitaxel 
resistance is not cell type specific and could apply to all cancers. The 
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chemotherapeutics used to develop the resistant models were also diverse, the most 
common were cisplatin (37.2%) and paclitaxel (20.4%) (Figure 2C). The other 31 
agents are diverse mechanistically, suggesting that when cells become resistant to any 
agent there are two distinct paths available, one which leads to cross resistance to 
cisplatin and the other to paclitaxel.   
 
Cisplatin combination chemotherapy is the cornerstone of treatment of ovarian 
carcinomas. Initial platinum responsiveness in ovarian cancer is high, but up to 80% 
of patients will eventually relapse and become platinum resistant (7). Clinical 
platinum resistance is variably defined in the clinic and as such it is difficult to make 
comparisons of treatment activity between trials. However, many second-line ovarian 
carcinoma studies use Markman’s criteria (8) where disease progression with a 
platinum free interval of less than 6 months is considered platinum resistant. Our 
search of the literature for single agent oxaliplatin salvage therapy in platinum-
resistant ovarian carcinoma identified 4 studies. The response rate (RR) of the 
platinum- resistant cohort was very low RR 8%, n = 91 compared to the platinum-
sensitive cohort RR 42%, n = 50 (p < 0.05 Chi-squared) (5). This suggests that there 
is no special activity of oxaliplatin in cisplatin-resistant cancer and correlates with the 
in vitro data suggesting that there is cross-resistance between cisplatin and oxaliplatin 
at clinically relevant levels of resistance. Oxaliplatin performed better in combination 
with other agents for the treatment of cisplatin-resistant cancer suggesting that the 
benefit of oxaliplatin may lie in its more favourable toxicity and ability to be 
combined with other drugs rather than an underlying activity in cisplatin resistance 
(5). Oxaliplatin therefore should not be considered broadly active in cisplatin-resistant 
cancer. 
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Our search of the literature for single agent paclitaxel salvage therapy in platinum-
resistant ovarian carcinoma identified 56 studies. In order to analyse if the inverse 
relationship between cisplatin and paclitaxel resistance observed in resistant cell 
models is apparent in clinical trials, the studies were divided into two groups, 
paclitaxel naïve ovarian cancer or paclitaxel pre-treated ovarian cancer.  The 
paclitaxel naïve cisplatin resistant patients had a higher response rate of 22%, n = 
1918 compared to the 8% response rate to oxaliplatin (p < 0.01). This again correlates 
with the in vitro data, there is a better response to the non-cross resistant agent 
paclitaxel than the cross resistant agent oxaliplatin (Figure 3). What was unexpected 
was platinum-resistant patients who have previously received paclitaxel therapy 
responded better to single agent paclitaxel (RR 35.3% n = 232) than the paclitaxel 
naïve patients (RR 22.7% n = 1918) (p <0.01 Chi-squared) (Figure 3) (6). Both 
cohorts of patients had very similar age, performance status, FIGO stage, and number 
of cycles of prior chemotherapy, there was a difference in histology but this did not 
account for this difference in response rates (6). Usually if patients have received a 
drug and experienced disease progression, they are less likely to respond to therapy 
with a subsequent exposure to the same drug. Although one must be cautious in 
interpreting these summary findings due to the potential for biases in pooling of 
patients across studies, if the findings do reflect the true clinical response to these 
agents, they suggest that initial co-treatment with platinum and paclitaxel may 
improve the outcome of paclitaxel salvage therapy. 
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Conclusions 
Oxaliplatin is not highly active in cisplatin resistant cancer, this appears to be due to 
cross resistance between cisplatin and oxaliplatin at clinically relevant levels of 
resistance. This provides some insight into the mechanisms of resistance to these 
agents, low level resistance provides cross resistance to both but at higher levels of 
resistance the mechanisms diverge. Paclitaxel has higher activity in cisplatin-resistant 
ovarian cancer, supporting the inverse resistance phenotype observed in cell models. 
Paclitaxel salvage chemotherapy has higher activity in ovarian cancer patients who 
have received prior paclitaxel therapy suggesting that alternating between agents 
could improve response rates. 
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Figure 1 – Cross resistance between A) cisplatin and oxaliplatin and B) cisplatin and carboplatin in cell 
models of acquired platinum resistance. The dotted line at 1 indicates the fold resistance of the parental cell 
lines. The solid line at 2 indicates the level of clinical platinum resistance.
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Figure 2 – Cross resistance between cisplatin and paclitaxel in A) cell models of acquired 
resistance. The dotted line at 1 indicates the fold resistance of the parental cell lines. The solid 
line at 2 indicates the level of clinical platinum resistance. Characteristics of the resistant 
models in the cisplatin/paclitaxel systematic review B) Types of carcinoma and C) 
Chemotherapeutics used to develop the resistant models. Reproduced from Stordal et al 2007, 
Cancer Treatment Reviews with permission from Elsevier Limited (6).
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cancer. Significant differences were determined by the Chi-
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